Resident Ethan Novek (center) of Innovator Energy was recently featured in Verizon Media’s “In the Know” docuseries. The series focuses on Gen Z changemakers who are reshaping the future and changing the world for the better. Watch the segment here.
Residents Sean O’Connell and Helen Hao of Aegle Research are shown with the newly acquired QUANTUM Cell Expansion System from Terumo BCT. The QUANTUM is a completely closed, fully automated system for the rapid expansion of a wide variety of both adherent and suspension cell cultures. The system is cGMP compliant and has achieved Clinical Manufacturing Device/Equipment status with the FDA. Aegle will use the QUANTUM to streamline the expansion and production of Aegle’s proprietary iNKT cell therapy for advanced solid tumor treatment.
Juvenescence Limited has partnered with Evgen Pharma to license its sulforaphane stabilization technology to use in several non-pharmaceutical applications led by its JuvLife(a Princeton Innovation Center BioLabs resident) division. Congratulations, JuvLife!
Women-Owned DIG Labs Poised to Launch Pet Health Technology
Resident DIG Labs, a companion animal life sciences company creating the future of personalized pet tech, was recently featured on njeda.com. Dig Labs is set to launch its first app, a real-time contactless ten-second wellness check for your dog. Learn how they credit New Jersey’s robust innovation ecosystem for their startup’s success.
Join us, along with our partner the Foundation for Health Advancement, on Wednesday, December 2 at 2 p.m. EST for a free event, “Navigating the Path to Startup Success.” Hear from founders and their investors who will share their lessons learned and successful steps in taking an idea from conceptual development through commercial launch, growth and eventual exit. Registration is a must!
Prud’homme cofounded the startup Optimeos Life Sciences(a Princeton Innovation Center BioLabs resident) in 2016 to make widely available flash nanoprecipitation, which originated from experiments conducted over two decades in Prud’homme’s lab. The company is creating improved delivery methods for medications targeting cancer, autoimmune disorders, diabetes, and diseases of the nervous system and the eye.
Princeton Innovation Center BioLabs welcomed in October new resident Atux Iskay Group LLC. Atux Iskay is developing proprietary PP2A activator technology and is the platform company for therapeutic focused sister companies. PP2A activators have shown efficacy in animal models of cancer, inflammation and neurodegenerative diseases. All of these areas have indications with major unmet medical needs and large markets. Core mission and technology focus on: drug discovery; pharmaceutical and medicinal chemistry and organic synthesis and synthetic technology.
Meet Our New Staff Member
Welcome Todd Sacks!
Please welcome our new Facilities Manager, Todd Sacks. Todd comes to us highly recommended and was most recently a facilities specialist at PTC Therapeutics. He will be responsible for our building systems and helping our residents with facilities-related issues.
Be sure to review BioLabs latest COVID-19 funding opportunities for both national/international research (non-financial research support too).